Showing 1-10 of 76 results for "".
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
https://practicaldermatology.com/programs/cme/data-driving-recent-guideline-updates-in-neoadjuvant-therapy-for-resectable-melanoma/36322/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma
https://practicaldermatology.com/programs/cme/implementing-guideline-concordant-care-for-a-patient-with-newly-diagnosed-braf-mutant-stage-iv-melanoma/36328/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
https://practicaldermatology.com/programs/cme/emerging-and-practice-changing-data-in-immunotherapy-strategies-for-melanoma/36330/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
https://practicaldermatology.com/programs/cme/clinical-data-prompting-guideline-updates-for-subcutaneous-icis-in-melanoma/36329/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
https://practicaldermatology.com/programs/cme/clinical-implications-of-neoadjuvant-therapy-guideline-updates-in-resectable-melanoma/36323/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Origins of AD: Recent Advances
https://practicaldermatology.com/issues/april-2025/origins-of-ad-recent-advances/35586/This paper reviews a study by Yadev et al. and further investigates the role of transient receptor potential ankyrin 1 (TRPA1) in the pathogenesis of atopic dermatitis (AD).Innovations in Oncology Learning Center: From Guidelines to Practice: Melanoma
https://practicaldermatology.com/programs/cme/innovations-in-oncology-learning-center-from-guidelines-to-practice-melanoma/33212/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.- Anisha Patel, MD, FAADhttps://practicaldermatology.com/profiles/anisha-patel-md-faad/OYVvRz/
Managing Skin Disease in Cancer Patients
https://practicaldermatology.com/topics/skin-cancer-photoprotection/managing-skin-disease-in-cancer-patients/19927/Skin reactions to cancer therapeutics can lead to difficult-to-manage rashes. Biologics can present an effective, appropriate option, but dermatologists need to know which biologics to select and when. Anisha Patel, MD provides an overview.Expanding Horizons in Skin Cancer Treatment
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/expanding-horizons-in-skin-cancer-treatment/18704/In Part 2 of this episode of Derm Insider, Host Neal Bhatia asks Anisha Patel, MD and Anthony Rossi, MD about advances in skin cancer therapies. Dr. Rossi discusses how to decide on the best regimens for the type of tumor being treated, and the importance of chemoprevention. They also talk more abou
- Prev
- Next